BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21538469)

  • 1. Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.
    Ai WZ; Kohrt HE; Timmerman J; Hwang J; Hsu FJ; Czerwinski DD; Taidi B; Levy R
    Am J Hematol; 2011 Jun; 86(6):515-8. PubMed ID: 21538469
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
    Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
    J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
    Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
    Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
    Zinzani PL; Stefoni V; Musuraca G; Tani M; Alinari L; Gabriele A; Marchi E; Pileri S; Baccarani M
    Cancer; 2004 May; 100(10):2190-4. PubMed ID: 15139063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
    Montoto S; Moreno C; Domingo-Doménech E; Estany C; Oriol A; Altés A; Besalduch J; Pedro C; Gardella S; Escoda L; Asensio A; Vivancos P; Galán P; de Sevilla AF; Ribera JM; Briones J; Colomer D; Campo E; Montserrat E; López-Guillermo A;
    Haematologica; 2008 Feb; 93(2):207-14. PubMed ID: 18223288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
    Domingo-Domènech E; González-Barca E; Estany C; Sureda A; Besalduch J; Fernández de Sevilla A
    Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.
    Palomera L; Azaceta G; Varo MJ; Soria J; Gutierrez M
    Haematologica; 1998 Nov; 83(11):1045-6. PubMed ID: 9864929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
    J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
    Marcus R; Imrie K; Solal-Celigny P; Catalano JV; Dmoszynska A; Raposo JC; Offner FC; Gomez-Codina J; Belch A; Cunningham D; Wassner-Fritsch E; Stein G
    J Clin Oncol; 2008 Oct; 26(28):4579-86. PubMed ID: 18662969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine versus cyclophosphamide, vincristine, and prednisone in recurrent low-grade lymphomas.
    Alliot C
    J Clin Oncol; 2003 Jul; 21(13):2626; author reply 2626-7. PubMed ID: 12829689
    [No Abstract]   [Full Text] [Related]  

  • 13. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
    Marcheselli L; Bari A; Anastasia A; Botto B; Puccini B; Dondi A; Carella AM; Alvarez I; Chiarenza A; Arcari A; Salvi F; Federico M
    Br J Haematol; 2015 May; 169(4):544-51. PubMed ID: 25817296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current immunochemotherapy strategies in follicular lymphoma.
    Giné E; Gutiérrez-García G; López-Guillermo A
    Adv Ther; 2010 Oct; 27(10):704-13. PubMed ID: 20820973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose therapy for follicular lymphoma revisited: not if, but when?
    Lister TA
    J Clin Oncol; 2003 Nov; 21(21):3894-6. PubMed ID: 14517186
    [No Abstract]   [Full Text] [Related]  

  • 18. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.
    Leo E; Scheuer L; Schmidt-Wolf IG; Kerowgan M; Schmitt C; Leo A; Baumbach T; Kraemer A; Mey U; Benner A; Parwaresch R; Ho AD
    Eur J Haematol; 2004 Oct; 73(4):251-7. PubMed ID: 15347311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab.
    Martin-Salces M; Canales MA; de Paz R; Hernandez-Navarro F
    Leuk Res; 2008 Jan; 32(1):199-200. PubMed ID: 17870157
    [No Abstract]   [Full Text] [Related]  

  • 20. Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma.
    Ghielmini M
    Cancer Treat Rev; 2005 Dec; 31(8):644-7. PubMed ID: 16289339
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.